

---

 COMMENTS AND  
 RESPONSES
 

---

**Response to  
 Comment on: Ramos-  
 Zavala et al. Effect of  
 Diacerein on Insulin  
 Secretion and  
 Metabolic Control in  
 Drug-Naïve Patients  
 With Type 2  
 Diabetes: A  
 Randomized Clinical  
 Trial. Diabetes Care  
 2011;34:1591-  
 1594**

**W**e thank Tobar et al. (1) for sharing the brief results and conclusions of an elegant study in an animal model of obesity and type 2 diabetes that allowed confirmation of the antihyperglycemic effect of diacerein, a medication frequently used in the treatment of rheumatic diseases, and the responsible mechanisms by which diacerein was able to reduce the chronic subclinical inflammation at the cellular level in liver, muscle, and adipose

tissue with improvement of glucose metabolism, inducing a reduction in hepatic glucose output. Contrary to those findings, in our study in drug-naïve patients with type 2 diabetes (2), insulin sensitivity was not improved, interleukin-6 levels were not significantly decreased, and diminution of triglycerides concentration was limited with diacerein administration. This may be due to differences in the inflammatory behavior between the studied models (animal and human) or to insufficient treatment duration, or may be, as was commented by Tobar et al., because hepatic glucose output was not measured, and this is an important evaluation. In any case, the above-mentioned limitations allow justification of other investigations under different conditions, independent of the beneficial effect on insulin secretion reported in our article that may support the potential use of diacerein in the treatment of patients with type 2 diabetes.

MARIA G. RAMOS-ZAVALA, MD, PHD<sup>1</sup>  
 MANUEL GONZÁLEZ-ORTIZ, MD, PHD<sup>1,2</sup>  
 ESPERANZA MARTÍNEZ-ABUNDIS, MD, PHD<sup>1,2</sup>  
 JOSÉ A. ROBLES-CERVANTES, MD, PHD<sup>1</sup>  
 ROBERTO GONZÁLEZ-LÓPEZ, MD, MSC<sup>1</sup>  
 NESTOR J. SANTIAGO-HERNÁNDEZ, MD<sup>1</sup>

From the <sup>1</sup>Medical Research Unit in Clinical Epidemiology, Specialties Hospital, Medical Unit of High Specialty, West National Medical Center, Mexican Institute of Social Security, Guadalajara,

Mexico; and the <sup>2</sup>Cardiovascular Research Unit, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Mexico.

Corresponding author: Manuel González-Ortiz, uiec@prodigy.net.mx.

DOI: 10.2337/dc11-2035

© 2012 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

---

**Acknowledgments**—No potential conflicts of interest relevant to this article were reported.

The authors thank Sharon Morey, Executive Editor, Scientific Communications, for English editorial assistance.

.....

**References**

1. Tobar N, Oliveira AG, Guadagnini D, et al. Comment on: Ramos-Zavala et al. Effect of diacerein on insulin secretion and metabolic control in drug-naïve patients with type 2 diabetes: a randomized clinical trial. *Diabetes Care* 2011;34:1591–1594 (Letter). *Diabetes Care* 2012;35:e13. DOI: 10.2337/dc11-1856
2. Ramos-Zavala MG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, González-López R, Santiago-Hernández NJ. Effect of diacerein on insulin secretion and metabolic control in drug-naïve patients with type 2 diabetes: a randomized clinical trial. *Diabetes Care* 2011;34:1591–1594